Eligibility criteria

Patient must:

a. Be 20 to 75 years of age, with a definitive histological diagnosis of PCa by needle biopsy.
b. Have intermediate-risk PCa according to D'Amico's stratification
c. Be previously untreated.
d. Demonstrate appropriate bone marrow, hepatic and renal function in laboratory tests within two weeks prior to registration.
   a) Leukocyte count ≥ 2,000/μL
   b) Hemoglobin level ≥ 10.0 g/dL
   c) Platelet count ≥ 10.0×10^4/μL
   d) Serum creatinine level ≤ 2.0 mg/dL
   e) ALT and AST levels ≤ 100 IU/L
e. Have an expected survival time of three months or longer from the start of the treatment.
f. Agree in writing to participate in this clinical study after receiving adequate explanation.